Floatz logo

Talaporfin

Mouth Cancer

Light Sciences LLCSmall moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
95/ 100

Competitive context

9 Active assets in the Mouth Cancer cohort.

Asset / SponsorPhaseRating
CIS-DIAMMINEDICHLOROPLATINUM II
Loren Mell, MD
Phase 2B
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Pembrolizumab
Loren Mell, MD
Phase 2CCC
FLUDEOXYGLUCOSE
Sanjiv Sam Gambhir
Phase 1/2CCC
(18F)FPPRGD2
Sanjiv Sam Gambhir
Phase 1/2CCC

View all 21 →

Same molecule, other indications

Talaporfin is also rated in:

liver and intrahepatic bile duct neoplasmDormant
BB
Indicative ·
68 / 100
View asset →
hepatocellular carcinomaDormant
BB
Indicative ·
64 / 100
View asset →
Liver MetastasisDormant
BB
Indicative ·
64 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →